Infant Term Birth Clinical Trial
Official title:
Safety and Efficacy of a New Term Infant Formula Supplemented With A Prebiotic: a Doubleblind, Randomized, Controlled Trial
NCT number | NCT02670863 |
Other study ID # | 14.15.INF |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | January 21, 2016 |
Est. completion date | May 2017 |
Verified date | October 2021 |
Source | Nestlé |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the safety and efficacy of the experimental formula supplemented with a prebiotic vs the control formula.
Status | Completed |
Enrollment | 239 |
Est. completion date | May 2017 |
Est. primary completion date | March 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A to 26 Days |
Eligibility | Inclusion Criteria: - Written Informed Consent - Infants whose parent(s)/LAR have reached the legal age of majority in the Philippines - Infants whose parent(s)/LAR are willing and able to comply with study requirements - Infants whose parent(s)/LAR are able to be contacted by telephone throughout the study - Healthy term, singleton infant at birth - Between 21 to 26 days post-natal age at enrollment visit - Weight-for-length and head circumference-for-age z-scores >/= - 3 and </= +3 according to WHO Child Growth Standards - Infants of parent(s)/LAR who have previously made the decision to formula feed their infant at the time of enrollment Exclusion Criteria: - Infants with conditions requiring infant feedings other than those specified in the protocol - Infants receiving complementary foods or liquids - Infants who have a medical condition or history that could increase the risk associated with study participation or interfere with the interpretation of study results - Infants who are presently receiving or have received medications that could interfere with the interpretation of study results - Infants or infants whose parents/LAR cannot be expected to comply with the protocol or with study procedures |
Country | Name | City | State |
---|---|---|---|
Philippines | Asian Hospital and Medical Center | Muntinlupa |
Lead Sponsor | Collaborator |
---|---|
Nestlé |
Philippines,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Growth | weight gain velocity | 150 days | |
Primary | Stool Consistency Score | 150 days | ||
Secondary | Weight | weight in grams | 150 days | |
Secondary | Average Daily Stool Frequency | 150 days | ||
Secondary | Fecal Microbiota | 150 days | ||
Secondary | Fecal Markers | 150 days | ||
Secondary | Adverse Events | 150 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03710551 -
Happy Smooth Study
|
N/A | |
Completed |
NCT02598817 -
Acceptability and Gastrointestinal Tolerance of a High-Sn-2 Infant Formula
|
||
Completed |
NCT03387124 -
Breastfeeding Study
|